Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy

NCT07502508 · Recruiting

Last updated 2026-05-28

This clinical trial is testing whether a new medication called icovamenib, taken daily for 12 weeks, can better control blood sugar levels in adults with type 2 diabetes who are not meeting their treatment goals while already using GLP-1-based therapies.

Status Recruiting Currently enrolling participants.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 60 people Planned (estimated).

Who can join Ages 18–70 · all sexes

Timeline Started 2026-04 · est. completion 2027-07

Where 16 sites · United States

What this study is testing ClinicalTrials.gov NCT07502508 ↗

Description as written by the study sponsor.

This is a phase 2 randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of icovamenib in participants with Type 2 Diabetes (T2D) not achieving glycemic targets despite Ozempic-based therapy.

Treatments tested

icovamenib 100 mg Drug

icovamenib 100 mg
Placebo Drug

Matching placebo

Main thing measured	To demonstrate that icovamenib 100 mg once daily for 12 weeks is superior to placebo for glycemic control
Sponsor	Biomea Fusion Inc.
Conditions studied	Type 2 Diabetes
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07502508 ↗